Resources
OUR EXPERIENCE AND COMMITMENT A Collaboration of Strengths
OUR EXPERIENCE AND COMMITMENT A Collaboration of Strengths

Merck has partnered with Samsung Bioepis—combining our individual strengths with a shared commitment to improve human health to deliver consistent, high-quality, affordable biosimilars.1

BOTH MERCK AND SAMSUNG BIOEPIS BRING DIFFERENT STRENGTHS TO THE COLLABORATION

By joining our individual strengths, Merck and Samsung Bioepis can help deliver high-quality, affordable biosimilars to patients around the world.

 
 
MERCK:
Guiding You Into the Era of Biosimilars
Our goal is to improve human health by delivering high-quality, rigorously studied, affordable biosimilars across multiple therapeutic areas.
  • We are bringing a full portfolio of biosimilars to market across multiple therapeutic areas
  • We have the experience and capabilities to bring these new options to patients
SAMSUNG BIOEPIS:
Global Leader in Developing and Manufacturing Quality Biosimilars
  • Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen
  • Expertise in large-scale biological product development and technical innovation
  • State-of-the-art manufacturing facilities in the European Union and the United States
  • Stringent standards of manufacturing practice used in order to be compliant with regulatory requirements and industry standards
References:
1. Merck Web site. 125 Year Anniversary. http://www.merck.com/about/featured-stories/125th_anniversary.html. Accessed March 29, 2016. 2. Samsung Bioepis. Samsung Bioepis and MSD enter biosimilars development and commercialization agreement. http://www.samsungbioepis.com/newsroom2/newsroom_3.html. Accessed May 3, 2016.